21928-40-5 Usage
Uses
Used in Pharmaceutical Research and Development:
Ethyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate is utilized as a synthetic intermediate for the development of potential drug candidates. Its intricate chemical structure allows researchers to explore its biological activity and pharmacological properties, which can be crucial for the discovery of new therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Ethyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate is employed as a versatile building block for the synthesis of various pharmaceutically relevant molecules. The presence of a hydroxyl group and a carboxylate moiety on its structure provides opportunities for further chemical modifications, enhancing its potential applications in drug discovery.
Used in Drug Synthesis:
Ethyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate is used as a key component in the synthesis of drugs, particularly those targeting specific biological pathways or receptors. Its unique structural features can be leveraged to create molecules with improved potency, selectivity, and pharmacokinetic properties.
Used in Chemical Libraries:
Ethyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate is also used in the creation of chemical libraries for high-throughput screening. Its inclusion in such libraries allows researchers to rapidly assess the biological activity of a wide range of structurally diverse compounds, facilitating the identification of promising drug leads.
Check Digit Verification of cas no
The CAS Registry Mumber 21928-40-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,9,2 and 8 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 21928-40:
(7*2)+(6*1)+(5*9)+(4*2)+(3*8)+(2*4)+(1*0)=105
105 % 10 = 5
So 21928-40-5 is a valid CAS Registry Number.
InChI:InChI=1/C15H17ClF3NO3/c1-2-23-13(21)20-7-5-14(22,6-8-20)10-3-4-12(16)11(9-10)15(17,18)19/h3-4,9,22H,2,5-8H2,1H3
21928-40-5Relevant academic research and scientific papers
Penfluridol preparation method
-
Paragraph 0144; 0145; 0146; 0147; 0148, (2017/02/24)
The invention discloses a penfluridol preparation method. The penfluridol preparation method includes the following steps of 1), subjecting succinic anhydride and fluorobenzene to Friedel-Crafts reaction prior to acid decomposition, and collecting a compound from the formula 2) as is shown in the description; 2), putting the compound in a solvent to collect a compound in formula 3) as is shown in the description in a solvent reduced through a reducing agent; 3), putting the compound into the fluorobenzene to perform the Friedel-Crafts reaction to collect a compound in the formula 4) as is shown in the description; subjecting the compound and ethyl chloroformate to action to generate a compound in formula 5) as is shown in the description; 5), subjecting the compound and a compound shown in formula (XVII) to reaction prior to hydrolyzation to collect a compound in formula 6) as is shown in the description; 6), performing reduction with the reducing agent prior to hydrolyzing a reduction product and then collecting penfluridol (I). The penfluridol preparation method is high in yield, low in cost, moderate in reaction condition, short in circuit, proper for industrial production, low in three wastes, easy to treat and suitable for industrial production.
INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
-
Page/Page column 27-28, (2010/11/24)
The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:
